12:00 AM
 | 
Jul 17, 2000
 |  BC Week In Review  |  Clinical News  |  Regulatory

Cytotoxic T lymphocyte regulatory update

TGEN received U.S. Patent No. 6,083,751 covering disease-specific CTLs engineered to express chimeric receptors that...

Read the full 51 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >